Login / Signup

Tumor Immunogenomic Features Determine Outcomes in Patients with Metastatic Colorectal Cancer Treated with Standard-of-Care Combinations of Bevacizumab and Cetuximab.

Federico InnocentiAkram YazdaniNaim RashidXueping QuFang-Shu OuScott Van BurenMonica M BertagnolliOmar KabbarahCharles David BlankeAlan P VenookHeinz-Josef LenzBenjamin G Vincent
Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
New immune features can be further evaluated to improve patient response. They provide the rationale for more effective immunotherapy strategies.
Keyphrases